Disease models of chronic inflammatory airway disease: applications and requirements for clinical trials

Zuzana Diamant*, Graham W. Clarke, Herman Pieterse, Juan Gispert

*Corresponding author for this work

    Research output: Contribution to journalReview articleAcademicpeer-review

    1 Citation (Scopus)

    Abstract

    Purpose of reviewThis review will discuss methodologies and applicability of key inflammatory models of respiratory disease in proof of concept or proof of efficacy clinical studies. In close relationship with these models, induced sputum and inflammatory cell counts will be addressed for phenotype-directed drug development. Additionally, important regulatory aspects regarding noninvestigational medicinal products used in bronchial challenges or clinical inflammatory models of respiratory disease will be highlighted.Recent findingsThe recognition of an ever increasing number of phenotypes and endotypes within conditions such as asthma and chronic obstructive pulmonary disease urges phenotyping of study populations already in early clinical phases of drug development. Apart from the choice of a relevant disease model, recent studies show that especially targeted therapies need to be tested in well defined disease subsets for adequate efficacy assessment. Noninvasive biomarkers, especially sputum inflammatory cell counts, aid phenotyping and are useful outcome measures for novel, targeted therapies.SummaryDisease phenotyping becomes increasingly important for efficient and cost-effective drug development and subsequent disease management. Inflammatory models of respiratory disease combined with sputum biomarkers are important tools in this approach.

    Original languageEnglish
    Pages (from-to)37-45
    Number of pages9
    JournalCurrent Opinion in Pulmonary Medicine
    Volume20
    Issue number1
    DOIs
    Publication statusPublished - Jan-2014

    Keywords

    • asthma
    • biomarkers
    • chronic obstructive pulmonary disease
    • drug development
    • human disease models of asthma and chronic obstructive pulmonary disease inflammatory models
    • phenotypes
    • sputum
    • OBSTRUCTIVE PULMONARY-DISEASE
    • ATOPIC ASTHMATIC SUBJECTS
    • LOW-DOSE ENDOTOXIN
    • INDUCED SPUTUM
    • INHALED ENDOTOXIN
    • HEALTHY-SUBJECTS
    • ALLERGEN CHALLENGE
    • VIRUS-INFECTION
    • OZONE EXPOSURE
    • COTTON DUST

    Cite this